Filana Therapeutics, Inc. (FLNA)
Healthcare
Biotechnology
1.00 $
+5.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Filana Therapeutics, Inc. (FLNA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 97.9% of the shares are freely tradable; institutional investors hold 28.7%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
28.7%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
11.0%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
97.9%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
13.9%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
48Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Group Inc | 4.92 | 2,375,589 | +3.8 | 12/31/2025 |
| Marshall Wace Asset Management Ltd | 4.17 | 2,012,543 | -4.9 | 03/31/2026 |
| Two Sigma Investments LLC | 4.12 | 1,988,814 | +209.6 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.00 | 1,930,943 | +0.0 | 03/31/2026 |
| BlackRock Inc | 2.93 | 1,414,514 | -0.4 | 03/31/2026 |
| Two Sigma Advisers, LLC | 1.98 | 954,800 | -0.7 | 12/31/2025 |
| Geode Capital Management, LLC | 1.23 | 596,242 | +9.2 | 03/31/2026 |
| D. E. Shaw & Co LP | 1.16 | 559,205 | +19.2 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.83 | 1,365,843 | +0.0 | 04/30/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 1.17 | 565,836 | +9.4 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.